Abstract: A system for reading an assay includes a camera and a processor. The assay is used as a test for the presence or absence of a reaction between a sample and a reagent. The assay is defined by a test area and a background area. The test area is, preferably, substantially circular with a diameter between about 0.1 mm and about 5 mm. The camera simultaneously captures a two-dimensional image of the test area and the background area. The processor determines a first color response from the background area and a second color response from the test area. The processor then calibrates the second color response according to the first color response and generates a result of the test according to the second color response. The system may also include a uniform field illuminator that provides a substantially uniform level of illumination across the assay.

Abstract: The present invention relates to markers for kidney disease.

Abstract: Analytical results obtained with microfluidic devices are improved by providing structural features in areas containing dry supported reagents, the structural features directing the flow of a sample over the area in a predetermined uniform manner and facilitating the purging of air.

Abstract: A device for detecting an analyte in a fluid sample includes a liquid permeable composition for making a physical separation between compositions of the sample or for reacting with components. The liquid permeable composition has adhesive properties and can be used to make a multi-layered test strip or the composition can be used in the sample wells of microfluidic devices.

Abstract: Assays in which samples of biological fluids are dispensed into the inlet port of a microfluidic device are improved in the accuracy and repeatability by dispensing the biological sample and/or associated liquids in small droplets and at timed intervals to control the operation of the microfluidic device.

Abstract: Methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using C-terminal fragments of adiponectin receptor R1. Methods of causing the secretion of insulin in healthy and diabetic patients using C-terminal fragments of adiponectin receptor R1 are also disclosed. In addition, methods are disclosed of increasing the insulin levels in healthy patients using C-terminal fragments of adiponectin receptor R1. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed.

Abstract: A microfluidic device containing liquid reagents having an extended shelf life contains the liquid reagents in micro-reservoirs that limit the escape of moisture to less than 10% over the shelf life of the device. The micro-reservoir preferably is made of polypropylene and covered with a metallized plastic film.

Abstract: A micro-liter liquid sample, particularly a biological sample, is analyzed in a device employing centrifugal and capillary forces. The sample is moved through one or more sample wells arrayed within a small flat chip via interconnecting capillary passageways. The passageways may be either hydrophobic or hydrophilic and may include hydrophobic or hydrophilic capillary stops.

Abstract: Certain monoclonal antibodies are able to detect urinary trypsin inhibitors (UTIs) that are characteristic of disease in humans. In particular, the UTIs include AMBK, Bikunin, Uristatin, Uristatin-1, Uristatin-2, as defined herein, also including the fragments and aggregates thereof.

Abstract: A micro-liter liquid sample, particularly a biological sample, is analyzed in a device employing centrifugal and capillary forces. The sample is moved through one or more sample wells arrayed within a small flat chip via interconnecting capillary passageways. The passageways may be either hydrophobic or hydrophilic and may include hydrophobic or hydrophilic capillary stops.

Abstract: A microfluidic device for analyzing biological samples is provided with a sample inlet section including an inlet port, a capillary passageway communication with the inlet port and with an inlet chamber. The inlet chamber includes means for uniformly distributing the sample liquid across the inlet chamber and purging the air initially contained therein.

Abstract: A microfluidic device containing liquid reagents having an extended shelf life contains the liquid reagents in micro-reservoirs that limit the escape of moisture to less than 10% over the shelf life of the device. The micro-reservoir preferably is made of polypropylene and covered with a metallized plastic film.

Abstract: Certain monoclonal antibodies are able to detect urinary trypsin inhibitors (UTIs) that are characteristic of disease in humans. In particular, the UTIs include AMBK, Bikunin, Uristatin, Uristatin-1, Uristatin-2, as defined herein, also including the fragments and aggregates thereof.

Abstract: Mixing of liquids in a microfluidic device is accomplished by dispensing the liquids into a first chamber to produce combined liquid. The liquids are thereafter discharged through at least one capillary from the first chamber into a second chamber for complete mixing.

Abstract: A microliter liquid sample, particularly a biological sample, is analyzed in a device employing centrifugal and capillary forces. The sample is moved by capillary forces into one or more metering wells which define the amount of the sample to be analyzed in subsequent steps. The defined amount of the sample is transferred from the metering wells to one or more conditioning and reagent wells for measuring the amount of an analyte contained in each metered amount of the sample.

Abstract: A microfluidic device provides separation of particles in a liquid sample, particularly, separation of a sample of whole blood into its components for further analysis. Separation into red blood cells and plasma occurs within a few seconds after the blood sample has been transferred into a separation chamber with the application of centrifugal force of less than about five times gravity. With the application of greater force measurement of hematocrit is possible.

Abstract: Disclosed is an assay for determining the presence and concentration of trypsin inhibitor in urine samples. The assay reagents, which may be used either in the liquid or dry states, include trypsin, a trypsin substrate and a polycarboxylic chelating agent. The inclusion of the chelating agent in the assay has been found to reduce variation in the assay results.

Abstract: A compound of the formula (I) wherein R1 is a protecting group for N?, R2 is a protecting group for NG, and R3 is aryl, and wherein the compound of formula (I) is a trypsin substrate such that trypsin cleaves the O—C single bond, which liberates R3—OH; a diagnostic device comprising same; a method for preparing the diagnostic device; and a method of using the diagnostic device to detect levels of urinary trypsin inhibitor in a biological sample; and a diagnostic kit for detecting levels of urinary trypsin inhibitor in a biological sample.

Abstract: Analytical results obtained with microfluidic devices are improved by providing structural features in areas containing dry supported reagents, the structural features directing the flow of a sample over the area in a predetermined uniform manner and facilitating the purging of air.

Abstract: A microfluidic device for analyzing biological samples is provided with a sample inlet section including an inlet port, a capillary passageway communicating with the inlet port and with an inlet chamber. The inlet chamber includes means for uniformly distributing the sample liquid across the inlet chamber and purging the air initially contained therein.